

Sub D1 Cont
C1
cancel -

-- an amount of at least one compound selected from the group consisting of interleukin-1 antagonists, TNF-alpha antagonists and combinations thereof, sufficient to eliminate or alleviate said irritant side-effect, and a cosmetically, dermatologically or pharmaceutically acceptable medium therefor, wherein the agent which produces the irritant side-effect is selected from the group consisting of alpha-keto acids, beta-keto acids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.

Sub D1 Cont
C2

8. (Amended) The composition of Claim 1, further comprising at least one active agent selected from the group consisting of an anti-bacterial, an antiparasitic agent, an antifungal agent, an anti-inflammatory agent, an antipruriginous agent, an anesthetic agent, an antiviral agent, a keratolytic agent, a free-radical scavenging agent, an antiseborrheic agent, an antidandruff agent, an anti-acne agent, an agent which modulates differentiation of skin, an agent which modulates proliferation of skin and an agent which modulates pigmentation of skin.

Sub D1 Cont
C3

10. (Twice Amended) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising
an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include an interleukin-1 antagonist or a TNF-alpha antagonist, and wherein said irritant agent is an active agent in said composition;

Sub D' Cont
C3
concl.
at least one compound selected from the group consisting of interleukin-1 antagonists, TNF alpha antagonists and combinations thereof, in an amount effective to antagonize said irritant side-effect;

and a cosmetically, dermatologically or pharmaceutically acceptable medium therefor, said compound inhibiting the IL-1-induced adhesion of macrophages to endothelial cells, inhibiting the IL-1-induced release of superoxide anions from neutrophils, inhibiting the TNF alpha-induced adhesion of macrophages to endothelial cells, inhibiting the TNF alpha-induced release of superoxide anions from neutrophils, inhibiting the mitogenic activity of TNF alpha by dermal fibroblasts, or inhibiting the release of interleukin-1 or TNF alpha by phorbol ester induced differentiated monocytes, and wherein the agent which produces an irritant side-effect is selected from the group consisting of alpha-keto acids, beta-keto acids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D, and depigmentation agents.

Sub D' Cont
C4
12. (Amended) The composition of Claim 10, further comprising at least one histamine antagonist, said histamine antagonist inhibiting the contraction of smooth muscles induced by the administration of histamine or inhibiting the release of histamine by stimulated mast cells.

Sub D' Cont
C5
17. (Amended) The composition of Claim 10, further comprising at least one active agent selected from the group consisting of an anti-bacterial agent, an antiparasitic agent, an antifungal agent, an anti-inflammatory agent, an antipruriginous agent, an

Sub D.
Cont
C5
conced

anesthetic agent, an antiviral agent, a keratolytic agent, a free-radical scavenging agent, a
• antiseborrheic agent, an antidandruff agent, an anti-acne agent, an agent which modulates
differentiation of skin, an agent which modulates proliferation of skin, and an agent which
modulates pigmentation of skin.

Sub D.
Cont
C6

19. (Amended) A composition suitable for pharmaceutical, cosmetic or
dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user
when utilized in a composition that does not include a TNF-alpha antagonist, and wherein
said irritant agent is an active agent in said composition;

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate
said irritant side-effect; and

a cosmetically, dermatologically or pharmaceutically acceptable medium therefor
wherein the agent which provides the irritant side-effect is selected from the group
consisting of alpha-keto acids, beta-keto acids, retinoids, anthralins, anthranoids,
peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.

20. (Amended) A composition suitable for pharmaceutical, cosmetic or
dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user
when utilized in a composition that does not include an interleukin-1 antagonist or a TNF-
alpha antagonist, and wherein said irritant agent is an active agent in said composition;

an amount of at least one interleukin-1 antagonist and at least one TNF-alpha antagonist, sufficient to eliminate or alleviate said irritant side-effect; and
a cosmetically, dermatologically or pharmaceutically acceptable medium therefor.

21. (Amended) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include an interleukin-1 antagonist, and wherein said irritant agent is an active agent in said composition;

an amount of at least one interleukin-1 antagonist, sufficient to eliminate or alleviate said irritant side-effect; and

a cosmetically, dermatologically or pharmaceutically acceptable medium therefor, said agent being selected from the group consisting of alpha-keto acids, beta-keto acids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.

Kindly add new claims 22-37 as follows:

22. (New) The composition of Claim 19, wherein the agent which produces an irritant side-effect is selected from the group consisting of alpha-hydroxy acids, beta-hydroxy acids, alpha-keto acids, beta-keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.

23. (New) The composition of Claim 19, further comprising at least one histamine antagonist.

24. (New) The composition of Claim 23, wherein the histamine antagonist is a heterocycle or a nitrogen compound having at least one benzene ring.

25. (New) The composition of Claim 19, wherein the amount of the compound ranges from about 0.000001 to 5% by weight relative to the total weight of the composition.

26. (New) The composition of Claim 19, wherein the amount of the compound ranges from about 0.0001 to 0.1% by weight relative to the total weight of the composition.

27. (New) The composition of Claim 19, wherein the cosmetically, pharmaceutically, or dermatologically acceptable medium comprises an aqueous, oil or aqueous alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a microemulsion, an aqueous gel, an anhydrous gel, a serum, or a dispersion of vesicles, microcapsules or microparticles.

28. (New) The composition of Claim 19, further comprising at least one active agent selected from the group consisting of anti-bacterial, antiparasitic, antifungal, anti-inflammatory, antipruriginous, anesthetic, antiviral, keratolytic, free-radical scavenging,

Sub D
Cont

C6
cont.

antiseborrheic, antidandruff and anti-acne agents and/or agents which modulate the differentiation and/or the proliferation and/or the pigmentation of skin.

Sub D1 Cont

29. (New) The composition of Claim 28, wherein the active agent is selected from the group consisting of lidocaine hydrochloride, antiparasitic agents and non-steroidal anti-inflammatory agents.

C6 cont.

30. (New) The composition of Claim 20, wherein the agent which produces an irritant side-effect is selected from the group consisting of alpha-hydroxy acids, beta-hydroxy acids, alpha-keto acids, beta-keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.

31. (New) The composition of Claim 20, further comprising at least one histamine antagonist.

32. (New) The composition of Claim 31, wherein the histamine antagonist is a heterocycle or a nitrogen compound having at least one benzene ring.

33. (New) The composition of Claim 20, wherein the amount of the compound ranges from about 0.000001 to 5% by weight relative to the total weight of the composition.

34. (New) The composition of Claim 20, wherein the amount of the compound ranges from about 0.0001 to 0.1% by weight relative to the total weight of the composition.

Sub D1
Cont

35. (New) The composition of Claim 20, wherein the cosmetically, pharmaceutically, or dermatologically acceptable medium comprises an aqueous, oil or aqueous alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a microemulsion, an aqueous gel, an anhydrous gel, a serum, or a dispersion of vesicles, microcapsules or microparticles.

C-6
conclude

36. (New) The composition of Claim 20, further comprising at least one active agent selected from the group consisting of anti-bacterial, antiparasitic, antifungal, anti-inflammatory, antipruriginous, anesthetic, antiviral, keratolytic, free-radical scavenging, antiseborrheic, antidandruff and anti-acne agents and/or agents which modulate the differentiation and/or the proliferation and/or the pigmentation of skin.

37. (New) The composition of Claim 36, wherein the active agent is selected from the group consisting of lidocaine hydrochloride, antiparasitic agents and non-steroidal anti-inflammatory agents.
